The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
about
Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaManagement of elderly and unfit patients with chronic lymphocytic leukemia.A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentInhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer ProgressionIdelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasChronic lymphocytic leukemia therapy: new targeted therapies on the wayReactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Targeting CK2-driven non-oncogene addiction in B-cell tumors.Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Current Treatment of Chronic Lymphocytic Leukemia.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ InhibitorsPI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.Recent therapeutic advances in chronic lymphocytic leukemia.MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway.Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
P2860
Q26779129-D285BF92-053E-4B0C-BF34-EDB524070012Q30243914-26969FAC-093A-4492-A331-9D0E605E3589Q33591830-C67EE6C0-4B60-4443-BDB3-6FC9CC41BA3AQ33607950-817C7091-15ED-4F1C-8ABA-D7AE660A9408Q33776641-C6C90B36-69DB-48AC-AFBB-38947643E3ACQ33821187-623419FA-550B-4CAE-B256-738D8F51BE6CQ37058203-592FC2E9-6E75-46CA-9097-C5E5515CE42CQ37113544-9100461A-F8D4-4987-B872-69DB5918A29BQ37457562-BF219864-F516-4031-9E18-444E9FBD80CAQ37457673-9CAC8718-6E4E-46E6-8572-EF0456A86FCFQ37587308-D57148CA-811F-4BDD-A3DF-CD39F06E0EACQ37725415-AD056EE3-FAB8-40F1-AC49-088E54D2C438Q37737793-F370CE46-605A-450C-9DF6-E3EAE0CE61EAQ38550810-AF1F6C05-A26A-4B5B-9449-B67AB8CDB727Q38597740-A21D1C5A-9856-456C-B6F7-F9D4F5923078Q38611244-11EAEC00-E288-4787-899D-18928A966EF7Q38646974-EAE00AF3-F5EE-45BB-9CF9-925225D5450EQ38797342-8E5EEB79-10D3-4067-A3C3-EFDD08BAE3D9Q38805440-95706337-FC66-4436-897C-7A3469417C87Q38851368-C186C72E-2BDB-426C-89CA-612998579A41Q38943877-24C428C3-98B7-4893-80F7-76A88AC14FE9Q39065374-7F3342A0-DAE3-4706-BA7B-9E22206EF472Q39129372-85128955-3A65-47B8-A7E8-A3526957ABF3Q39226787-E6302510-93CB-49DD-AF6A-895B7550E7DAQ39375290-E6D7B1FB-3A8F-4FAF-9460-3F8CF4DFC14FQ40575812-7C0A088F-7297-4969-801B-65A9C7B03961Q41537666-73C5EA08-2F2F-45A3-AC1A-7C6A1565C727Q41992697-6232B31D-D7A1-4B52-BC3C-7B22C7CEE758Q41994564-953920B1-5F4F-494F-A0BF-D6CB55C25C9DQ46055970-E2CC47B2-B9CE-4546-926A-6E92C32E4685Q46318389-9ADB031D-7798-4FA1-A3D2-176A8DECDEFCQ47222575-8C694C57-4443-424E-890D-721A6D32A231Q47388561-41318B58-B0FE-4ED9-86D9-456FFB9C939CQ47445525-F03ACB9D-0350-446A-9033-2167FA3CEEC8Q47754054-07297174-F388-4E1E-BB1B-EAC72CD301F7Q47898168-A311BB3E-9577-4623-9F1F-CCC1FBBB6D34Q47932240-4AE99A75-56FB-4DBF-93FC-B6216F36F0F3Q49887083-981B7E47-7126-4DCF-91C9-7FC2F2454F2CQ51738230-287D3C83-3417-46E1-B29A-B7CF4EBD3E64Q52664561-D3095876-3A57-49E3-BFBA-A56AF5247491
P2860
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@ast
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@en
type
label
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@ast
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@en
prefLabel
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@ast
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@en
P2093
P2860
P356
P1433
P1476
The phosphoinositide-3-kinase ...... and promotes apoptosis in CLL.
@en
P2093
J A Burger
K Balakrishnan
M J Keating
P2860
P2888
P304
P356
10.1038/LEU.2015.105
P577
2015-04-28T00:00:00Z